Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000072.xml
Download PDF
Semin Reprod Med 2024; 42(03): 228-238
DOI: 10.1055/s-0044-1791725
DOI: 10.1055/s-0044-1791725
Review Article
Inflammatory Bowel Disease and Reproductive Health: A Focus on Pregnancy Planning and Outcomes
Abstract
Reproductive counseling is crucial for women's health, especially for those with inflammatory bowel disease (IBD), which often affects younger patients during their childbearing years. Patients with IBD need special considerations when planning for pregnancy. Preconception counseling is important as it helps patients make informed decisions about pregnancy and allows for optimal management of IBD before, during, and after pregnancy. In this review, we aim to provide guidance for managing and treating patients with IBD throughout the preconception, pregnancy, and postpartum period.
Publication History
Article published online:
11 October 2024
© 2024. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology 2017; 152 (02) 313-321.e2
- 2 Ng SC, Shi HY, Hamidi N. et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017; 390 (10114): 2769-2778
- 3 Shah SC, Khalili H, Gower-Rousseau C. et al. Sex-based differences in incidence of inflammatory bowel diseases-pooled analysis of population-based studies from Western countries. Gastroenterology 2018; 155 (04) 1079-1089.e3
- 4 Lassi ZS, Imam AM, Dean SV, Bhutta ZA. Preconception care: screening and management of chronic disease and promoting psychological health. Reprod Health 2014; 11 (Suppl 3, Suppl 3): S5
- 5 de Lima A, Zelinkova Z, Mulders AG, van der Woude CJ. Preconception care reduces relapse of inflammatory bowel disease during pregnancy. Clin Gastroenterol Hepatol 2016; 14 (09) 1285-1292.e1
- 6 Tavernier N, Fumery M, Peyrin-Biroulet L, Colombel JF, Gower-Rousseau C. Systematic review: fertility in non-surgically treated inflammatory bowel disease. Aliment Pharmacol Ther 2013; 38 (08) 847-853
- 7 Cornish JA, Tan E, Teare J. et al. The effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy and delivery: a systematic review. Dis Colon Rectum 2007; 50 (08) 1128-1138
- 8 Friedman S, Nielsen J, Nøhr EA, Jølving LR, Nørgård BM. Comparison of time to pregnancy in women with and without inflammatory bowel diseases. Clin Gastroenterol Hepatol 2020; 18 (07) 1537-1544.e1
- 9 Rajaratnam SG, Eglinton TW, Hider P, Fearnhead NS. Impact of ileal pouch-anal anastomosis on female fertility: meta-analysis and systematic review. Int J Colorectal Dis 2011; 26 (11) 1365-1374
- 10 Waljee A, Waljee J, Morris AM, Higgins PD. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut 2006; 55 (11) 1575-1580
- 11 Bartels SA, DʼHoore A, Cuesta MA, Bensdorp AJ, Lucas C, Bemelman WA. Significantly increased pregnancy rates after laparoscopic restorative proctocolectomy: a cross-sectional study. Ann Surg 2012; 256 (06) 1045-1048
- 12 Beyer-Berjot L, Maggiori L, Birnbaum D, Lefevre JH, Berdah S, Panis Y. A total laparoscopic approach reduces the infertility rate after ileal pouch-anal anastomosis: a 2-center study. Ann Surg 2013; 258 (02) 275-282
- 13 Gorgun E, Cengiz TB, Aytac E. et al. Does laparoscopic ileal pouch-anal anastomosis reduce infertility compared with open approach?. Surgery 2019; 166 (04) 670-677
- 14 Laube R, Selinger CP, Seow CH. et al. Australian inflammatory bowel disease consensus statements for preconception, pregnancy and breast feeding. Gut 2023; 72 (06) 1040-1053
- 15 Mahadevan U, Robinson C, Bernasko N. et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group. Inflamm Bowel Dis 2019; 25 (04) 627-641
- 16 Hernandez-Nieto C, Sekhon L, Lee J, Gounko D, Copperman A, Sandler B. Infertile patients with inflammatory bowel disease have comparable in vitro fertilization clinical outcomes to the general infertile population. Gynecol Endocrinol 2020; 36 (06) 554-557
- 17 Laube R, Tran Y, Paramsothy S, Leong RW. Assisted reproductive technology in Crohn's disease and ulcerative colitis: a systematic review and meta-analysis. Am J Gastroenterol 2021; 116 (12) 2334-2344
- 18 Pabby V, Oza SS, Dodge LE. et al. In vitro fertilization is successful in women with ulcerative colitis and ileal pouch anal anastomosis. Am J Gastroenterol 2015; 110 (06) 792-797
- 19 Ban L, Tata LJ, Humes DJ, Fiaschi L, Card T. Decreased fertility rates in 9639 women diagnosed with inflammatory bowel disease: a United Kingdom population-based cohort study. Aliment Pharmacol Ther 2015; 42 (07) 855-866
- 20 Timmer A, Bauer A, Dignass A, Rogler G. Sexual function in persons with inflammatory bowel disease: a survey with matched controls. Clin Gastroenterol Hepatol 2007; 5 (01) 87-94
- 21 Nguyen GC, Seow CH, Maxwell C. et al; IBD in Pregnancy Consensus Group, Canadian Association of Gastroenterology. The Toronto Consensus Statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology 2016; 150 (03) 734-757.e1
- 22 Pugliese D, Privitera G, Gisbert JP, Chaparro M. New drugs for the treatment of IBD during conception, pregnancy, and lactation. Dig Liver Dis 2024; 56 (02) 235-241
- 23 Banerjee A, Scarpa M, Pathak S. et al. Inflammatory bowel disease therapies adversely affect fertility in men - a systematic review and meta-analysis. Endocr Metab Immune Disord Drug Targets 2019; 19 (07) 959-974
- 24 Kim YJ. Glucocorticoid therapy in assisted reproduction. Clin Exp Reprod Med 2021; 48 (04) 295-302
- 25 Winger EE, Reed JL, Ashoush S, El-Toukhy T, Taranissi M. Die-off ratio correlates with increased TNF-α:IL-10 ratio and decreased IVF success rates correctable with Humira. Am J Reprod Immunol 2012; 68 (05) 428-437
- 26 Lédée-Bataille N, Dubanchet S, Coulomb-L'hermine A, Durand-Gasselin I, Frydman R, Chaouat G. A new role for natural killer cells, interleukin (IL)-12, and IL-18 in repeated implantation failure after in vitro fertilization. Fertil Steril 2004; 81 (01) 59-65
- 27 Marri SR, Ahn C, Buchman AL. Voluntary childlessness is increased in women with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13 (05) 591-599
- 28 Sulz MC, Doulberis M, Fournier N. et al; SIBDCS Group. Childlessness in patients with inflammatory bowel disease - data from the Prospective Multi-center Swiss IBD Cohort Study. J Gastrointestin Liver Dis 2023; 32 (04) 460-468
- 29 Walldorf J, Brunne S, Gittinger FS, Michl P. Family planning in inflammatory bowel disease: childlessness and disease-related concerns among female patients. Eur J Gastroenterol Hepatol 2018; 30 (03) 310-315
- 30 Laube R, Yau Y, Selinger CP. et al. Knowledge and attitudes towards pregnancy in females with inflammatory bowel disease: an international, multi-centre study. J Crohn's Colitis 2020; 14 (09) 1248-1255
- 31 Loftus Jr EV. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004; 126 (06) 1504-1517
- 32 Orholm M, Munkholm P, Langholz E, Nielsen OH, Sørensen TI, Binder V. Familial occurrence of inflammatory bowel disease. N Engl J Med 1991; 324 (02) 84-88
- 33 Peeters M, Nevens H, Baert F. et al. Familial aggregation in Crohn's disease: increased age-adjusted risk and concordance in clinical characteristics. Gastroenterology 1996; 111 (03) 597-603
- 34 Joossens M, Van Steen K, Branche J. et al. Familial aggregation and antimicrobial response dose-dependently affect the risk for Crohn's disease. Inflamm Bowel Dis 2010; 16 (01) 58-67
- 35 Moller FT, Andersen V, Wohlfahrt J, Jess T. Familial risk of inflammatory bowel disease: a population-based cohort study 1977-2011. Am J Gastroenterol 2015; 110 (04) 564-571
- 36 Santos MPC, Gomes C, Torres J. Familial and ethnic risk in inflammatory bowel disease. Ann Gastroenterol 2018; 31 (01) 14-23
- 37 Akolkar PN, Gulwani-Akolkar B, Heresbach D. et al. Differences in risk of Crohn's disease in offspring of mothers and fathers with inflammatory bowel disease. Am J Gastroenterol 1997; 92 (12) 2241-2244
- 38 Zelinkova Z, Stokkers PC, van der Linde K, Kuipers EJ, Peppelenbosch MP, van der Woude CP. Maternal imprinting and female predominance in familial Crohn's disease. J Crohns Colitis 2012; 6 (07) 771-776
- 39 Costa-Santos MP, Frias-Gomes C, Oliveira A. et al. Conjugal inflammatory bowel disease: a systematic review and European survey. Ann Gastroenterol 2021; 34 (03) 361-369
- 40 Laharie D, Debeugny S, Peeters M. et al. Inflammatory bowel disease in spouses and their offspring. Gastroenterology 2001; 120 (04) 816-819
- 41 Andreu M, Márquez L, Domènech E. et al; Spanish GETECCU group (ENEIDA project). Disease severity in familial cases of IBD. J Crohns Colitis 2014; 8 (03) 234-239
- 42 Bennett RA, Rubin PH, Present DH. Frequency of inflammatory bowel disease in offspring of couples both presenting with inflammatory bowel disease. Gastroenterology 1991; 100 (06) 1638-1643
- 43 Carbonnel F, Macaigne G, Beaugerie L, Gendre JP, Cosnes J. Crohn's disease severity in familial and sporadic cases. Gut 1999; 44 (01) 91-95
- 44 Bandoli G, Singh N, Strouse J. et al. Mediation of adverse pregnancy outcomes in autoimmune conditions by pregnancy complications: a mediation analysis of autoimmune conditions and adverse pregnancy outcomes. Arthritis Care Res (Hoboken) 2020; 72 (02) 256-264
- 45 Cornish J, Tan E, Teare J. et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 2007; 56 (06) 830-837
- 46 O'Toole A, Nwanne O, Tomlinson T. Inflammatory bowel disease increases risk of adverse pregnancy outcomes: a meta-analysis. Dig Dis Sci 2015; 60 (09) 2750-2761
- 47 Tandon P, Govardhanam V, Leung K, Maxwell C, Huang V. Systematic review with meta-analysis: risk of adverse pregnancy-related outcomes in inflammatory bowel disease. Aliment Pharmacol Ther 2020; 51 (03) 320-333
- 48 Abhyankar A, Ham M, Moss AC. Meta-analysis: the impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 38 (05) 460-466
- 49 Bröms G, Granath F, Linder M, Stephansson O, Elmberg M, Kieler H. Birth outcomes in women with inflammatory bowel disease: effects of disease activity and drug exposure. Inflamm Bowel Dis 2014; 20 (06) 1091-1098
- 50 Kim MA, Kim YH, Chun J. et al. The influence of disease activity on pregnancy outcomes in women with inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis 2021; 15 (05) 719-732
- 51 Mahadevan U, Long MD, Kane SV. et al; Crohn's Colitis Foundation Clinical Research Alliance. Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease. Gastroenterology 2021; 160 (04) 1131-1139
- 52 Mogadam M, Korelitz BI, Ahmed SW, Dobbins III WO, Baiocco PJ. The course of inflammatory bowel disease during pregnancy and postpartum. Am J Gastroenterol 1981; 75 (04) 265-269
- 53 Pedersen N, Bortoli A, Duricova D. et al; European Crohn-Colitis Organisation-ECCO-Study Group of Epidemiology Committee-EpiCom. The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women. Aliment Pharmacol Ther 2013; 38 (05) 501-512
- 54 de Lima-Karagiannis A, Zelinkova-Detkova Z, van der Woude CJ. The effects of active IBD during pregnancy in the era of novel IBD therapies. Am J Gastroenterol 2016; 111 (09) 1305-1312
- 55 Aboubakr A, Riggs AR, Jimenez D, Mella MT, Dubinsky MC. Identifying patient priorities for preconception and pregnancy counseling in IBD. Dig Dis Sci 2021; 66 (06) 1829-1835
- 56 Bar-Oz B, Moretti ME, Boskovic R, O'Brien L, Koren G. The safety of quinolones–a meta-analysis of pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol 2009; 143 (02) 75-78
- 57 Caro-Patón T, Carvajal A, Martin de Diego I, Martin-Arias LH, Alvarez Requejo A, Rodríguez Pinilla E. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol 1997; 44 (02) 179-182
- 58 Drugs and Lactation Database. (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Metronidazole. [Updated 2023 Sep 15]. Accessed September 25, 2024 at: https://www.ncbi.nlm.nih.gov/books/NBK501315/
- 59 Nørgård B, Czeizel AE, Rockenbauer M, Olsen J, Sørensen HT. Population-based case control study of the safety of sulfasalazine use during pregnancy. Aliment Pharmacol Ther 2001; 15 (04) 483-486
- 60 Nørgård B, Fonager K, Pedersen L, Jacobsen BA, Sørensen HT. Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study. Gut 2003; 52 (02) 243-247
- 61 Torres J, Chaparro M, Julsgaard M. et al. European Crohn's and colitis guidelines on sexuality, fertility, pregnancy, and lactation. J Crohns Colitis 2023; 17 (01) 1-27
- 62 Drugs and Lactation Database. (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Mesalamine. [Updated 2024 Feb 15]. Accessed September 25, 2024 at: https://www.ncbi.nlm.nih.gov/books/NBK501318/
- 63 Carmichael SL, Shaw GM, Ma C, Werler MM, Rasmussen SA, Lammer EJ. National Birth Defects Prevention Study. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol 2007; 197 (06) 585.e1-585.e7 , discussion 683–684, e1–e7
- 64 Odufalu FD, Long M, Lin K, Mahadevan U. PIANO Investigators from the Crohn's and Colitis Foundation (CCF) Clinical Research Alliance recruited patients for their respective centers for participant enrollment. Exposure to corticosteroids in pregnancy is associated with adverse perinatal outcomes among infants of mothers with inflammatory bowel disease: results from the PIANO registry. Gut 2022; 71 (09) 1766-1772
- 65 Park-Wyllie L, Mazzotta P, Pastuszak A. et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62 (06) 385-392
- 66 Pradat P, Robert-Gnansia E, Di Tanna GL, Rosano A, Lisi A, Mastroiacovo P. Contributors to the MADRE database. First trimester exposure to corticosteroids and oral clefts. Birth Defects Res A Clin Mol Teratol 2003; 67 (12) 968-970
- 67 Beaulieu DB, Ananthakrishnan AN, Issa M. et al. Budesonide induction and maintenance therapy for Crohn's disease during pregnancy. Inflamm Bowel Dis 2009; 15 (01) 25-28
- 68 Vestergaard T, Jørgensen SMD, Christensen LA, Julsgaard M. Pregnancy outcome in four women with inflammatory bowel disease treated with budesonide MMX. Scand J Gastroenterol 2018; 53 (12) 1459-1462
- 69 Drugs and Lactation Database. (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Prednisolone. [Updated 2024 Apr 15]. Accessed September 25, 2024 at: https://www.ncbi.nlm.nih.gov/books/NBK501076/#
- 70 Akbari M, Shah S, Velayos FS, Mahadevan U, Cheifetz AS. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19 (01) 15-22
- 71 Casanova MJ, Chaparro M, Domènech E. et al. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol 2013; 108 (03) 433-440
- 72 Hutson JR, Matlow JN, Moretti ME, Koren G. The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy. J Obstet Gynaecol 2013; 33 (01) 1-8
- 73 Kanis SL, Modderman S, Escher JC. et al; Initiative on Crohns and Colitis (ICC). Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life. Gut 2021; 70 (07) 1266-1274
- 74 Julsgaard M, Christensen LA, Gibson PR. et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology 2016; 151 (01) 110-119
- 75 Chaparro M, Verreth A, Lobaton T. et al. Long-term safety of in utero exposure to anti-TNFα drugs for the treatment of inflammatory bowel disease: results from the Multicenter European TEDDY Study. Am J Gastroenterol 2018; 113 (03) 396-403
- 76 Drugs and Lactation Database. (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Mercaptopurine. [Updated 2024 Feb 15]. Accessed September 25, 2024 at: https://www.ncbi.nlm.nih.gov/books/NBK501015/
- 77 Kozlowski RD, Steinbrunner JV, MacKenzie AH, Clough JD, Wilke WS, Segal AM. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med 1990; 88 (06) 589-592
- 78 Martínez Lopez JA, Loza E, Carmona L. Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding). Clin Exp Rheumatol 2009; 27 (04) 678-684
- 79 Weber-Schoendorfer C, Chambers C, Wacker E. et al; Network of French Pharmacovigilance Centers. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol 2014; 66 (05) 1101-1110
- 80 Drugs and Lactation Database. (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Methotrexate. [Updated 2023 Dec 15]. Accessed September 25, 2024 at: https://www.ncbi.nlm.nih.gov/books/NBK501341/
- 81 Baumgart DC, Sturm A, Wiedenmann B, Dignass AU. Uneventful pregnancy and neonatal outcome with tacrolimus in refractory ulcerative colitis. Gut 2005; 54 (12) 1822-1823
- 82 Branche J, Cortot A, Bourreille A. et al. Cyclosporine treatment of steroid-refractory ulcerative colitis during pregnancy. Inflamm Bowel Dis 2009; 15 (07) 1044-1048
- 83 Korelitz BI. Inflammatory bowel disease and pregnancy. Gastroenterol Clin North Am 1998; 27 (01) 213-224
- 84 Luu M, Benzenine E, Doret M. et al. Continuous anti-TNFα use throughout pregnancy: possible complications for the mother but not for the fetus. a retrospective cohort on the French National Health Insurance Database (EVASION). Am J Gastroenterol 2018; 113 (11) 1669-1677
- 85 Bar-Gil Shitrit A, Ben Yaʼacov A, Livovsky DM. et al. Exposure to vedolizumab in IBD pregnant women appears of low risk for mother and neonate: a first prospective comparison study. Am J Gastroenterol 2019; 114 (07) 1172-1175
- 86 Bell C, Tandon P, Lentz E, Marshall JK, Narula N. Systematic review and meta-analysis: Safety of vedolizumab during pregnancy in patients with inflammatory bowel disease. J Gastroenterol Hepatol 2021; 36 (10) 2640-2648
- 87 Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler 2011; 17 (08) 958-963
- 88 Moens A, van der Woude CJ, Julsgaard M. et al. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Aliment Pharmacol Ther 2020; 51 (01) 129-138
- 89 Wils P, Seksik P, Stefanescu C. et al; PREGNANCY-GETAID Study Group. Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study. Aliment Pharmacol Ther 2021; 53 (04) 460-470
- 90 Eli Lilly and Company. Highlights of prescribing information: OMVOH (mirikizumab-mrkz). FDA. Accessed September 25, 2024 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761279s000lbl.pdf (2023)
- 91 Abbie Inc. Highlights of prescribing information: SKYRIZI® (risankizumab-rzaa) injection. FDA. Accessed September 25, 2024 at: https://www.accessdata.fda.gov/spl/data/3e0de6fd-0db0-4d0a-95bb-3c280a1e54ee/3e0de6fd-0db0-4d0a-95bb-3c280a1e54ee.xml (2022).
- 92 Pfizer. Highlights of prescribing information: Xeljanz/Xeljanz XR (tofacitinib). FDA. Accessed September 25, 2024 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203214s018lbl.pdf (2018)
- 93 Abbvie Inc. Highlights of prescribing information: Rinvoq (upadacitinib). FDA. Accessed September 25, 2024 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf (2022)
- 94 Mahadevan U, Dubinsky MC, Su C. et al. Outcomes of pregnancies with maternal/paternal exposure in the tofacitinib safety databases for ulcerative colitis. Inflamm Bowel Dis 2018; 24 (12) 2494-2500
- 95 Celgene. Highlights of prescribing information: Zeposia (ozanimod). FDA. Accessed September 25, 2024 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf (2020)
- 96 Abbvie inc. Highlights of prescribing information: VELSIPITYTM (Etrasimod) tablets. FDA. Accessed September 25, 2024 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216956s000lbl.pdf (2023)
- 97 Brondfield MN, Mahadevan U. Inflammatory bowel disease in pregnancy and breastfeeding. Nat Rev Gastroenterol Hepatol 2023; 20 (08) 504-523
- 98 Klajnbard A, Szecsi PB, Colov NP. et al. Laboratory reference intervals during pregnancy, delivery and the early postpartum period. Clin Chem Lab Med 2010; 48 (02) 237-248
- 99 Bálint A, Berényi A, Farkas K. et al. Pregnancy does not affect fecal calprotectin concentration in healthy women. Turk J Gastroenterol 2017; 28 (03) 171-175
- 100 Julsgaard M, Hvas CL, Gearry RB. et al. Fecal calprotectin is not affected by pregnancy: clinical implications for the management of pregnant patients with inflammatory bowel disease. Inflamm Bowel Dis 2017; 23 (07) 1240-1246
- 101 Rottenstreich A, Mishael T, Granovsky SG. et al. Clinical utility of fecal calprotectin in monitoring disease activity and predicting relapse in pregnant patients with inflammatory bowel diseases. Eur J Intern Med 2020; 77: 105-110
- 102 Tandon P, Leung K, Yusuf A, Huang VW. Noninvasive methods for assessing inflammatory bowel disease activity in pregnancy: a systematic review. J Clin Gastroenterol 2019; 53 (08) 574-581
- 103 Palacios C, Kostiuk LK, Peña-Rosas JP. Vitamin D supplementation for women during pregnancy. Cochrane Database Syst Rev 2019; 7 (07) CD008873
- 104 Wei SQ, Qi HP, Luo ZC, Fraser WD. Maternal vitamin D status and adverse pregnancy outcomes: a systematic review and meta-analysis. J Matern Fetal Neonatal Med 2013; 26 (09) 889-899
- 105 Viswanathan M, Urrutia RP, Hudson KN, Middleton JC, Kahwati LC. Folic acid supplementation to prevent neural tube defects: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2023; 330 (05) 460-466
- 106 Rolnik DL, Wright D, Poon LC. et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017; 377 (07) 613-622
- 107 Shmidt E, Dubinsky MC. Inflammatory bowel disease and pregnancy. Am J Gastroenterol 2022; 117 (10S, 10s): 60-68
- 108 DeBolt CA, Gottlieb ZS, Rao MG. et al. Low-dose aspirin use does not increase disease activity in pregnant patients with inflammatory bowel disease. Dig Dis Sci 2024; 69 (05) 1803-1807
- 109 Caprilli R, Gassull MA, Escher JC. et al; European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 2006; 55 (Suppl 1, Suppl 1): i36-i58
- 110 Horsthuis K, Bipat S, Bennink RJ, Stoker J. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: meta-analysis of prospective studies. Radiology 2008; 247 (01) 64-79
- 111 De Lima A, Galjart B, Wisse PHA, Bramer WM, van der Woude CJ. Does lower gastrointestinal endoscopy during pregnancy pose a risk for mother and child? - a systematic review. BMC Gastroenterol 2015; 15: 15
- 112 Hepner DL, Siddiqui UD. Endoscopy and sedation. Am J Gastroenterol 2022; 117 (10S, 10s): 33-38
- 113 Shergill AK, Ben-Menachem T, Chandrasekhara V. et al; ASGE Standard of Practice Committee. Guidelines for endoscopy in pregnant and lactating women. Gastrointest Endosc 2012; 76 (01) 18-24
- 114 Killeen S, Gunn J, Hartley J. Surgical management of complicated and medically refractory inflammatory bowel disease during pregnancy. Colorectal Dis 2017; 19 (02) 123-138
- 115 Lightner AL, Mathis KL. Surgery in pregnancy. Am J Gastroenterol 2022; 117 (10S, 10s): 53-59
- 116 Hansen AT, Erichsen R, Horváth-Puhó E, Sørensen HT. Inflammatory bowel disease and venous thromboembolism during pregnancy and the postpartum period. J Thromb Haemost 2017; 15 (04) 702-708
- 117 Kim YH, Pfaller B, Marson A, Yim HW, Huang V, Ito S. The risk of venous thromboembolism in women with inflammatory bowel disease during pregnancy and the postpartum period: a systematic review and meta-analysis. Medicine (Baltimore) 2019; 98 (38) e17309
- 118 Foulon A, Dupas JL, Sabbagh C. et al. Defining the most appropriate delivery mode in women with inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2017; 23 (05) 712-720
- 119 Malhi G, Tandon P, Perlmutter JW, Nguyen G, Huang V. Risk factors for postpartum disease activity in women with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2022; 28 (07) 1090-1099
- 120 Yu A, Friedman S, Ananthakrishnan AN. Incidence and predictors of flares in the postpartum year among women with inflammatory bowel disease. Inflamm Bowel Dis 2020; 26 (12) 1926-1932
- 121 Agrawal I, Mehendale AM, Malhotra R. Risk factors of postpartum depression. Cureus 2022; 14 (10) e30898
- 122 Neuendorf R, Harding A, Stello N, Hanes D, Wahbeh H. Depression and anxiety in patients with inflammatory bowel disease: a systematic review. J Psychosom Res 2016; 87: 70-80
- 123 Vigod SN, Kurdyak P, Brown HK. et al. Inflammatory bowel disease and new-onset psychiatric disorders in pregnancy and post partum: a population-based cohort study. Gut 2019; 68 (09) 1597-1605
- 124 Section on Breastfeeding. Breastfeeding and the use of human milk. Pediatrics 2012; 129 (03) e827-e841
- 125 Kane S, Lemieux N. The role of breastfeeding in postpartum disease activity in women with inflammatory bowel disease. Am J Gastroenterol 2005; 100 (01) 102-105
- 126 Prentice R, Flanagan E, Wright EK. et al. Vedolizumab and ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero. Clin Gastroenterol Hepatol 2024; S1542 -3565 (24) 00252 -0
- 127 Cheent K, Nolan J, Shariq S, Kiho L, Pal A, Arnold J. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis 2010; 4 (05) 603-605
- 128 Goulden B, Chua N, Parker E, Giles I. A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying anti-rheumatic drugs in utero. Rheumatology (Oxford) 2022; 61 (10) 3902-3906
- 129 Fitzpatrick T, Alsager K, Sadarangani M. et al; Special Immunization Clinic Network investigators. Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents: a prospective cohort study from the Canadian Immunization Research Network. Lancet Child Adolesc Health 2023; 7 (09) 648-656